Overview
Gastrointestinal anthrax is a severe infection caused by Bacillus anthracis, primarily affecting the gastrointestinal tract. It can lead to significant morbidity and mortality if not promptly recognized and treated 23.Diagnosis
Clinical Presentation: Symptoms include abdominal pain, vomiting, and bloody diarrhea, progressing to severe sepsis 2.
Laboratory Tests: Elevated white blood cell count, presence of B. anthracis in stool or blood cultures 2.
Imaging: Abdominal CT may show thickening of bowel walls and lymphadenopathy 2.
Biopsy and Histopathology: Essential for definitive diagnosis, showing characteristic edema, hemorrhage, and necrosis 2.
Serology and PCR: Useful for confirming B. anthracis infection but not always immediately available 2.Management
Antibiotics: First-line treatment includes ciprofloxacin or doxycycline; adjunctive therapy with penicillin or amoxicillin may be necessary 2.
Supportive Care: Aggressive fluid resuscitation, management of shock, and surgical intervention for complications like bowel perforation 2.
Antitoxin: Administration of anthrax immune globulin intravenous (AIGIV) or anthrax vaccine absorbed (AVA) in severe cases 2.Special Populations
Pediatrics: Limited specific data; management follows adult guidelines with close monitoring 1.
Elderly: Increased risk of complications; tailored supportive care and vigilant monitoring are crucial 2.
Comorbidities: Patients with underlying gastrointestinal disorders may present atypically; thorough evaluation is essential 2.Key Recommendations
Enhance Training and Preparedness: Emergency department physicians and primary care providers should undergo regular bioterrorism training, including drills and lectures, to improve recognition and response to gastrointestinal anthrax (Evidence: Moderate 23).
Prompt Diagnostic Workup: Utilize a combination of clinical assessment, laboratory tests, imaging, and histopathology for accurate diagnosis (Evidence: Moderate 2).
Early Aggressive Treatment: Initiate broad-spectrum antibiotics early, consider adjunctive therapies, and provide comprehensive supportive care to mitigate mortality (Evidence: Moderate 2).References
1 Schäppi MG, Staiano A, Milla PJ, Smith VV, Dias JA, Heuschkel R et al.. A practical guide for the diagnosis of primary enteric nervous system disorders. Journal of pediatric gastroenterology and nutrition 2013. link
2 Leiba A, Drayman N, Amsalem Y, Aran A, Weiss G, Leiba R et al.. Establishing a high level of knowledge regarding bioterrorist threats in emergency department physicians: methodology and the results of a national bio-preparedness project. Prehospital and disaster medicine 2007. link
3 Moye PK, Pesik N, Terndrup T, Roe J, Weissman N, Kiefe C et al.. Bioterrorism training in U.S. emergency medicine residencies: has it changed since 9/11?. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2007. link
4 Alexander GC, Larkin GL, Wynia MK. Physicians' preparedness for bioterrorism and other public health priorities. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2006. link
5 Alder SC, Clark JD, White GL, Talboys S, Mottice S. Physician preparedness for bioterrorism recognition and response: a Utah-based needs assessment. Disaster management & response : DMR : an official publication of the Emergency Nurses Association 2004. link
6 Bu'Lock AJ, Vaillant C, Dockray GJ, Bu'Lock JD. A rational approach to the fixation of peptidergic nerve cell bodies in the gut using parabenzoquinone. Histochemistry 1982. link